文献速递中药与中成药合理使用中医儿科

体外序贯代谢与体内生物药剂学分析筛选小儿柴葛退热口服液质量标志物

Screening quality markers (Q-markers) of Xiaoer Chaige Tuire Oral Liquid by in vitro sequential metabolism and in vivo biopharmaceutical analysis.
PubMed 文献 · Phytomedicine · 2023-04-30

该研究采用体外序贯代谢模型(人工胃液、肠液、肠道菌群、Caco-2细胞单层和肝S9)结合体内生物药剂学分析,追踪小儿柴葛退热口服液(XCT)的体内生物活性成分,以筛选潜在质量标志物(Q-marker)。

要点

  • 建立体外序贯代谢与体内生物药剂学分析联用的Q-marker筛选策略。
  • 多数筛选出的化合物显示抗炎和抗流感病毒活性。

核心结论

  • 建立了基于体外序贯代谢与体内生物药剂学分析追踪体内生物活性成分的XCT潜在Q-marker筛选策略。
  • 共筛选出12个化合物作为XCT的潜在Q-marker,为质量控制与开发提供物质基础。

研究设计与样本

  • 采用体外代谢模型(人工胃液、肠液、肠道菌群、Caco-2细胞单层和肝S9)模拟XCT主要成分体内代谢。
  • 采用HPLC-DAD定量测定XCT制剂及序贯代谢样品主要成分,UPLC-QExactive-HF-x-Orbitrap-MS定性测定大鼠血浆中体内成分及大鼠肝S9代谢物。

主要发现

  • 除黄芩苷和黄芩素外多数化合物在人工胃液中稳定;芍药内酯苷、甘草酸、没食子酸和黄芩素在人工肠液中不稳定。
  • 大豆苷、甘草苷和染料木苷被肠道菌群水解为相应苷元大豆苷元、甘草素和染料木素。
  • 7个化合物(苯甲酸、葛根素、3'-甲氧基葛根素、芍药苷、东莨菪内酯、大豆苷元和甘草素)在Caco-2细胞单层模型中吸收良好,并经肝S9系统羟基化和糖基化代谢。

关键数值与推荐

  • 最终筛选12个潜在Q-marker:葛根素、大豆苷元、苯甲酸、黄芩苷、黄芩素、汉黄芩苷、汉黄芩素、木蝴蝶素A、3'-甲氧基葛根素、芍药苷、东莨菪内酯和甘草素。
  • 多数经体外和体内代谢研究筛选的化合物显示抗炎和抗流感病毒活性。

临床怎么用

  • 筛选出的12个潜在Q-marker可用于XCT的质量控制。
  • 该策略可为中药复方制剂的质量标志物筛选提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Xiaoer Chaige Tuire Oral Liquid (XCT) is a preparation composed of 7 traditional Chinese medicines including Bupleuri Radix, Puerariae Lobatae Radix, Scutellariae Radix, Gypsum Fibrosum, Artemisiae Annuae Herba, Paeoniae Radix Alba and Glycyrrhizae Radix Et Rhizoma Praeparata Cum Melle in proportion. According to traditional Chinese medicine theory, it has the function of dispelling wind evil and relieving exterior syndrome, clearing summer heat and dampness, and reducing internal heat. So, it is indicated for pediatric upper respiratory tract infection caused by exogenous wind-heat. Modern pharmacological studies have indicated that XCT has a variety of activities such as anti-inflammation and antivirus. PURPOSE: To screen potential quality markers (Q-markers) of XCT by tracking in vivo bioactive compounds concomitantly using in vitro sequential metabolism and in vivo biopharmaceutical analysis. METHODS: In vitro metabolic models including artificial gastric juice, intestinal juice, intestinal microbiota, Caco-2 cell monolayer and liver S9 were employed to simulate metabolism of main compounds of XCT in the body. High performance liquid chromatography with diode-array detection (HPLC-DAD) was used to quantitatively determine main components of XCT preparation and its sequential metabolism samples. Ultra performance liquid chromatography with QExactive Orbitrap tandem mass spectrometry (UPLC-QExactive-HF-x-Orbitrap-MS) was used to qualitatively determine in vivo components of XCT preparation in rat plasma and metabolites obtained with liver S9 fraction of rats. RESULTS: Twenty-five compounds were identified from the preparation of XCT. Sequential in vitro metabolism studies indicated that most of these compounds except baicalin and baicalein were stable in artificial gastric juice, albiflorin, glycyrrhizic acid, gallic acid and baicalein were unstable in artificial intestinal juice, daidzin, liquiritin and genistin were hydrolyzed into their aglycones daidzein, liquiritigenin and genistein by intestinal microbiota, and 7 compounds thereout including benzoic acid, puerarin, 3'-methoxypuerarin, paeoniflorin, scopoletin, daidzein and liquiritigenin were shown to be well absorbed with Caco-2 cell monolayer model. These 7 compounds were demonstrated to be metabolized via hydroxylation and glycosylation by liver S9 system. Ten components of XCT preparation including puerarin, baicalin, wogonoside, benzoic acid, daidzein, baicalein, wogonin, oroxylin A, isoscopoletin and isoliquiritigenin were identified from rat plasma by in vivo biopharmaceutical analysis. Most of the compounds screened with both in vitro and in vivo metabolic studies were shown to be active against inflammation and influenza virus. CONCLUSIONS: A screening strategy for potential quality markers (Q-markers) of XCT preparation based on tracking in vivo bioactive compounds using the combination of in vitro sequential metabolism and in vivo biopharmaceutical analysis was established. With this strategy, a total of 12 compounds including puerarin, daidzein, benzoic acid, baicalin, baicalein, wogonoside, wogonin, oroxylin A, 3'-methoxypuerarin, paeoniflorin, scopoletin and liquiritigenin were screened to be potential Q-markers of XCT, which provides a material basis for quality control and development of XCT.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Liu S, Ding P, Wu M, et al. Screening quality markers (Q-markers) of Xiaoer Chaige Tuire Oral Liquid by in vitro sequential metabolism and in vivo biopharmaceutical analysis. Phytomedicine. 2023. PMID: 37163902. doi:10.1016/j.phymed.2023.154844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。